Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bleeding in the Brain Clear all
Completed Phase 2 Interventional

Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage

NCT01563445
View directory record Official record
Conditions
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Interventions
activated recombinant human factor VII, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Jul 24, 2026, 12:49 AM EDT
Completed Phase 1 Interventional Results available

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

NCT03000283
View directory record Official record
Conditions
Cerebral Hemorrhage, Cerebral Edema, Intracerebral Hemorrhage, Stroke
Interventions
Conivaptan
Drug
Lead sponsor
Jesse Corry
Other
Eligibility
19 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Jul 24, 2026, 12:49 AM EDT
Recruiting Phase 4 Interventional

Comparing the Safety and Efficacy of Apixaban and Rivaroxaban

NCT06953726
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 24, 2026, 12:49 AM EDT
Completed No phase listed Observational

Effect of Ischemic Strokes on Recovery From Intracerebral Hemorrhages

NCT01417117
View directory record Official record
Conditions
Hemorrhage; Intracerebral, Nontraumatic, Ischemic Strokes, Diffusion Weighted Imaging Lesions
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
19 Years to 79 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Jul 24, 2026, 12:49 AM EDT
Completed Phase 1 Interventional

Efficacy of Percutaneous SPG Block in Aneurysmal SAH

NCT04331938
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Headache
Interventions
Regional anesthetic SPG block-bilateral
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Jul 24, 2026, 12:49 AM EDT
Completed Phase 2 Interventional

Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)

NCT02323685
View directory record Official record
Conditions
Cerebral Ischemia
Interventions
SANGUINATE™
Biological
Lead sponsor
Prolong Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jul 24, 2026, 12:49 AM EDT
Completed No phase listed Observational Results available

Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

NCT04681482
View directory record Official record
Conditions
Atrial Fibrillation, Obesity, Anticoagulants
Interventions
Apixaban
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
107,383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Jul 24, 2026, 12:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Factors Influencing Readmission Rates of Acute Traumatic Subdural Hematoma in the Elderly

NCT03878043
View directory record Official record
Conditions
Traumatic Subdural Hematoma
Interventions
Follow-up Care
Other
Lead sponsor
Tarik Wasfie, MD
Industry
Eligibility
18 Years to 105 Years
Enrollment
167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Jul 24, 2026, 12:49 AM EDT
Not listed No phase listed Observational

Effect of Different Intravenous Fluids on Post-operative Chronic Subdural Hematoma Size and Recurrence

NCT03831997
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Dextrose 5% W/ Sodium Chloride 0.225%
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jul 24, 2026, 12:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Analysis of the Use of TEG in Stroke Patients

NCT02494726
View directory record Official record
Conditions
Ischemic Stroke, Brain Hemorrhage
Interventions
Thromboelastography
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Jul 24, 2026, 12:49 AM EDT
Active, not recruiting Not applicable Interventional

CHAMPION-AF Clinical Trial

NCT04394546
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
95
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 24, 2026, 12:49 AM EDT
Not listed Not applicable Interventional

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

NCT00006055
View directory record Official record
Conditions
Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
1 Year to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 12:49 AM EDT
Completed Phase 2 Interventional

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)

NCT00111085
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
10
States / cities
Peoria, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Jul 24, 2026, 12:49 AM EDT
Completed Phase 2 Interventional

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

NCT00075959
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
NXY-059
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
64
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Jul 24, 2026, 12:49 AM EDT
Recruiting Phase 2 Interventional

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

NCT07175428
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
REGN7508, REGN9933, Apixaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
40
States / cities
Dothan, Alabama • Fairhope, Alabama • Covina, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 24, 2026, 12:49 AM EDT
Completed Phase 3 Interventional

Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm

NCT00007605
View directory record Official record
Conditions
Atrial Fibrillation, Cerebrovascular Accident, Death, Sudden
Interventions
Amiodarone, Sotalol
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
28
States / cities
Tucson, Arizona • No. Little Rock, Arkansas • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2011 · Synced Jul 24, 2026, 12:49 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Aspirin in Reducing Events in the Elderly

NCT01038583
View directory record Official record
Conditions
Functional Disability, Dementia, Heart Disease, Stroke, Cancer, Bleeding, Depression
Interventions
100 mg enteric-coated aspirin, Placebo
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
65 Years and older
Enrollment
19,114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
33
States / cities
Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Jul 24, 2026, 12:49 AM EDT
Terminated Not applicable Interventional

Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury

NCT01810276
View directory record Official record
Conditions
Traumatic Head Injury, Intracranial Hemmorhage, Anti-platelet Therapy
Interventions
Saline, Platelets
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Jul 24, 2026, 12:49 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.

NCT01251263
View directory record Official record
Conditions
Menstrual Migraines, Menstrual Bleeding, Menstrual Spotting
Interventions
Estradiol or Placebo
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2010 · Synced Jul 24, 2026, 12:49 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study

NCT00589953
View directory record Official record
Conditions
Infant, Premature, Erythropoietin, Brain Injury, Intraventricular Hemorrhage, Periventricular Leukomalacia, Neurodevelopmental Outcomes, Randomized Clinical Trial
Interventions
Erythropoietin, Saline placebo
Drug
Lead sponsor
Atlantic Health System
Other
Eligibility
Up to 24 Hours
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Jul 24, 2026, 12:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Dantrolene in Subarachnoid Hemorrhage

NCT01024972
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Cerebral Vasospasm
Interventions
Dantrolene, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Jul 24, 2026, 12:49 AM EDT
Completed Not applicable Interventional

DCS Study in Extremely Premature Newborns

NCT04367181
View directory record Official record
Conditions
Premature Birth, Extremely Low Birth Weight, Infant, Small for Gestational Age, Intracerebral Hemorrhage
Interventions
Diffuse Correlation Spectroscopy (DCS), Amplitude Integrated Electroencephalography (aEEG)
Device
Lead sponsor
Maria Angela Franceschini
Other
Eligibility
0 Hours to 72 Hours
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 24, 2026, 12:49 AM EDT
Not listed Phase 4 Interventional

IV Double and Triple Concentrated Nicardipine for Stroke and ICH

NCT00325793
View directory record Official record
Conditions
Hypertension
Interventions
Nicardipine
Drug
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2006 · Synced Jul 24, 2026, 12:49 AM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Jul 24, 2026, 12:49 AM EDT